Fundraising Fox
/Companies
Sign in

Adventris Pharmaceuticals

YC W23

Baltimore, US · Founded 2022 · 7 employees · 8 known investors

Find your way into Adventris Pharmaceuticals

Sign up to see every warm intro you have to Adventris Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Adventris Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Adventris is a biotechnology company developing cancer immunotherapy treatments.

Also known as Elimivax

BiotechHealthtechHealthcareTherapeuticsDrug discoveryOncologyUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W23)

Adventris Pharmaceuticals was founded in 2022 by Jen Herbach, William Collis, Mark Yarchoan, and Jenny Lesser Herbach.

JHJen Herbach
Jen HerbachCEO & Co-FounderJen Herbach has over a decade of experience in oncology drug development at biotechnology companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a master's degree from the University of Cambridge.
WCWilliam Collis
William CollisCo-FounderWilliam Collis previously founded Genji, a data platform. He holds an MBA from Harvard Business School and graduated from Amherst College, where he met co-founders Jen Herbach and Mark Yarchoan.
MYMark Yarchoan
Mark YarchoanFounderMark Yarchoan is an Associate Professor of Medical Oncology at Johns Hopkins with NCI-funded research in immunotherapy development, particularly cancer vaccines. He has conducted clinical trials of immunotherapy agents including neoantigen-targeted approaches.
JLJenny Lesser Herbach
Jenny Lesser HerbachCEO & Co-Founder

Investors · 8

Blackbird BioventuresreportedBaltimore

How we know: Y Combinator's founder network · Not right? Tell us

Felicis VenturesreportedSan Francisco · $500K – $15M

How we know: Y Combinator's founder network · Not right? Tell us

Illumina VenturesreportedFoster City

How we know: funding news · Not right? Tell us

Khosla VenturesreportedMenlo Park · $100K – $20M

How we know: Y Combinator's founder network · Not right? Tell us

Peak XV PartnersreportedBengaluru · $100K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

Refactor CapitalreportedBurlingame · $1M – $2M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Venture Investment AssociatesreportedPeapack

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 7

Velorum TherapeuticsVelorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
AlixiaAlixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.
Eris BiotechEris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.
Notable LabsNotable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Numerion LabsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.

Companies working in the same space as Adventris Pharmaceuticals.

Legal entities · 1

corporate structure
Adventris Pharmaceuticals, Inc.

In the news

Adventris Pharmaceuticals - We make cancer vaccines!ycombinator.com · Jan 2023

Frequently asked questions

What does Adventris Pharmaceuticals do?
Adventris is a biotechnology company developing cancer immunotherapy treatments.
Who founded Adventris Pharmaceuticals?
Adventris Pharmaceuticals was founded by Jen Herbach, William Collis, Mark Yarchoan, Jenny Lesser Herbach in 2022.
Who are Adventris Pharmaceuticals's investors?
Adventris Pharmaceuticals's investors include Y Combinator, Blackbird Bioventures, Felicis Ventures, Illumina Ventures, Khosla Ventures, Peak XV Partners, Refactor Capital, Venture Investment Associates.
Where is Adventris Pharmaceuticals headquartered?
Adventris Pharmaceuticals is headquartered in Baltimore, US.